<a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms">We love to hear from our listeners. Send us a message. </a>On this week's episode of the Business of Biotech, Sean Ainsworth, CEO and Chairman at Immusoft, talks about transitioning from the research bench to entrepreneurship, his M&A experiences as a biotech founder, and why engineered B cell therapies offer a better, more patient-friendly administration for lysosomal storage diseases currently treated with enzyme replacement therapies. Sean also discusses FDA pathways, incentives, and agency engagement, and offers thoughts on the regulatory outlook for cell and gene therapies.     Access this and hundreds of episodes of the Business of Biotech videocast under the <a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'>Business of Biotech</a> tab at lifescienceleader.com. Subscribe to our monthly <a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'>Business of Biotech newsletter</a>. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: <a href='https://www.linkedin.com/in/bencomer/'>https://www.linkedin.com/in/bencomer/</a>

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

Engineering B Cells With Immusoft's Sean Ainsworth

Business Of Biotech

AI Chapters

AI Insights

Reviews